GMAB — Genmab A/S Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapHigh Flyer

Annual income statement for Genmab A/S, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	R2021 December 31st	R2022 December 31st	2023 December 31st	R2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	fx Final	fx Final	fx Final	Final	Final
Revenue
Total Revenue	1,338	2,050	2,391	3,121	3,720
Cost of Revenue
Gross Profit	1,338	2,050	2,358	2,978	3,482
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	869	1,164	1,619	2,149	2,655
Operating Profit	470	886	772	972	1,065
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	623	982	818	1,326	1,204
Provision for Income Taxes
Net Income After Taxes	470	771	632	1,133	963
Net Income Before Extraordinary Items
Net Income	470	771	632	1,133	963
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	470	771	632	1,133	963
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	7.12	11.7	9.58	18.2	18
Dividends per Share